Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 44


Vaccination of boys or catch-up of girls above 11 years of age with the HPV-16/18 AS04-adjuvanted vaccine: where is the greatest benefit for cervical cancer prevention in Italy?

Bonanni P, Gabutti G, Demarteau N, Boccalini S, La Torre G.

BMC Infect Dis. 2015 Sep 17;15:377. doi: 10.1186/s12879-015-1067-9.


A cost-utility analysis of cervical cancer screening and human papillomavirus vaccination in the Philippines.

Guerrero AM, Genuino AJ, Santillan M, Praditsitthikorn N, Chantarastapornchit V, Teerawattananon Y, Alejandria M, Toral JA.

BMC Public Health. 2015 Jul 30;15:730. doi: 10.1186/s12889-015-2046-1.


Association Study between Cervical Lesions and Single or Multiple Vaccine-Target and Non-Vaccine Target Human Papillomavirus (HPV) Types in Women from Northeastern Brazil.

Chagas BS, Comar M, Gurgel AP, Paiva S, Seraceni S, de Freitas AC, Crovella S.

PLoS One. 2015 Jul 15;10(7):e0132570. doi: 10.1371/journal.pone.0132570. eCollection 2015.


Hoarseness-causes and treatments.

Reiter R, Hoffmann TK, Pickhard A, Brosch S.

Dtsch Arztebl Int. 2015 May 8;112(19):329-37. doi: 10.3238/arztebl.2015.0329.


Naturally Occurring Capsid Protein Variants of Human Papillomavirus Genotype 31 Represent a Single L1 Serotype.

Bissett SL, Godi A, Fleury MJ, Touze A, Cocuzza C, Beddows S.

J Virol. 2015 Aug;89(15):7748-57. doi: 10.1128/JVI.00842-15. Epub 2015 May 20.


Seroepidemiology of Human Papillomavirus 16 (HPV16) L2 and Generation of L2-Specific Human Chimeric Monoclonal Antibodies.

Wang JW, Jagu S, Wu WH, Viscidi RP, Macgregor-Das A, Fogel JM, Kwak K, Daayana S, Kitchener H, Stern PL, Gravitt PE, Trimble CL, Roden RB.

Clin Vaccine Immunol. 2015 Jul;22(7):806-16. doi: 10.1128/CVI.00799-14. Epub 2015 May 13.


Cross-Reactivity, Epitope Spreading, and De Novo Immune Stimulation Are Possible Mechanisms of Cross-Protection of Nonvaccine Human Papillomavirus (HPV) Types in Recipients of HPV Therapeutic Vaccines.

Nakagawa M, Greenfield W, Moerman-Herzog A, Coleman HN.

Clin Vaccine Immunol. 2015 Jul;22(7):679-87. doi: 10.1128/CVI.00149-15. Epub 2015 May 6. Review.


A chimeric 18L1-45RG1 virus-like particle vaccine cross-protects against oncogenic alpha-7 human papillomavirus types.

Huber B, Schellenbacher C, Jindra C, Fink D, Shafti-Keramat S, Kirnbauer R.

PLoS One. 2015 Mar 19;10(3):e0120152. doi: 10.1371/journal.pone.0120152. eCollection 2015.


The role of acquired immunity in the spread of human papillomavirus (HPV): explorations with a microsimulation model.

Matthijsse SM, van Rosmalen J, Hontelez JA, Bakker R, de Kok IM, van Ballegooijen M, de Vlas SJ.

PLoS One. 2015 Feb 2;10(2):e0116618. doi: 10.1371/journal.pone.0116618. eCollection 2015.


Sequential cisplatin therapy and vaccination with HPV16 E6E7L2 fusion protein in saponin adjuvant GPI-0100 for the treatment of a model HPV16+ cancer.

Peng S, Wang JW, Karanam B, Wang C, Huh WK, Alvarez RD, Pai SI, Hung CF, Wu TC, Roden RB.

PLoS One. 2015 Jan 5;10(1):e116389. doi: 10.1371/journal.pone.0116389. eCollection 2015.


Immunoprevention of human papillomavirus-associated malignancies.

Wang JW, Hung CF, Huh WK, Trimble CL, Roden RB.

Cancer Prev Res (Phila). 2015 Feb;8(2):95-104. doi: 10.1158/1940-6207.CAPR-14-0311. Epub 2014 Dec 8. Review.


Comparison of adaptive and innate immune responses induced by licensed vaccines for Human Papillomavirus.

Herrin DM, Coates EE, Costner PJ, Kemp TJ, Nason MC, Saharia KK, Pan Y, Sarwar UN, Holman L, Yamshchikov G, Koup RA, Pang YY, Seder RA, Schiller JT, Graham BS, Pinto LA, Ledgerwood JE.

Hum Vaccin Immunother. 2014;10(12):3446-54. doi: 10.4161/hv.34408.


The efficacy and duration of vaccine protection against human papillomavirus: a systematic review and meta-analysis.

Deleré Y, Wichmann O, Klug SJ, van der Sande M, Terhardt M, Zepp F, Harder T.

Dtsch Arztebl Int. 2014 Sep 1;111(35-36):584-91. doi: 10.3238/arztebl.2014.0584. Review.


Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland.

Pollock KG, Kavanagh K, Potts A, Love J, Cuschieri K, Cubie H, Robertson C, Cruickshank M, Palmer TJ, Nicoll S, Donaghy M.

Br J Cancer. 2014 Oct 28;111(9):1824-30. doi: 10.1038/bjc.2014.479. Epub 2014 Sep 2.


Co-infection with HPV types from the same species provides natural cross-protection from progression to cervical cancer.

Sobota RS, Ramogola-Masire D, Williams SM, Zetola NM.

Infect Agent Cancer. 2014 Aug 12;9:26. doi: 10.1186/1750-9378-9-26. eCollection 2014.


Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates.

Lang Kuhs KA, Porras C, Schiller JT, Rodriguez AC, Schiffman M, Gonzalez P, Wacholder S, Ghosh A, Li Y, Lowy DR, Kreimer AR, Poncelet S, Schussler J, Quint W, van Doorn LJ, Sherman ME, Sidawy M, Herrero R, Hildesheim A, Safaeian M; Costa Rica Vaccine Trial Group.

Am J Epidemiol. 2014 Sep 15;180(6):599-607. doi: 10.1093/aje/kwu168. Epub 2014 Aug 19.


Too late to vaccinate? The incremental benefits and cost-effectiveness of a delayed catch-up program using the 4-valent human papillomavirus vaccine in Norway.

Burger EA, Sy S, Nygård M, Kristiansen IS, Kim JJ.

J Infect Dis. 2015 Jan 15;211(2):206-15. doi: 10.1093/infdis/jiu413. Epub 2014 Jul 23.


New cervical cancer screening guidelines: was the annual pap too much of a good thing?

Fields MM.

J Adv Pract Oncol. 2013 Jan;4(1):59-64. Review. No abstract available.


Efficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial.

Hildesheim A, Wacholder S, Catteau G, Struyf F, Dubin G, Herrero R; CVT Group.

Vaccine. 2014 Sep 3;32(39):5087-97. doi: 10.1016/j.vaccine.2014.06.038. Epub 2014 Jul 10.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk